Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1.0 to $80.0 for Hims & Hers Health over the last 3 months.

Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

Live Updates Live Coverage Has Ended Bullish on Meta 12:09 pm by Gerelyn Terzo Analysts at Wall Street firm Citigroup are ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...